A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...
The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
That's still possible but no longer required.) For treatment-resistant depression, patients usually get the esketamine nasal spray twice a week for one to four weeks. Then they take it once a week ...
“Over the past 20 years, we’ve been losing the battle to depression with rates of depression nearly doubling in the [United States],” Gregory Mattingly, MD, principal investigator in ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...
This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...
According to the Arizona Department of Transportation, parts of I-10 and I-17 will be closed for work on improvement projects along Phoenix-area freeways. Gina Maravilla caught up with starting ...